Head-To-Head Survey: Integrated BioPharma (OTCMKTS:INBP) & Dominari (NASDAQ:DOMH)

Integrated BioPharma (OTCMKTS:INBP) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, analyst recommendations, profitability and institutional ownership.

Analyst Ratings

This is a summary of current ratings and price targets for Integrated BioPharma and Dominari, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integrated BioPharma	0	0	0	0	0.00
Dominari	1	0	0	0	1.00

Volatility and Risk

Integrated BioPharma has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Dominari has a beta of 0.8, indicating that its share price is 20% less volatile than the S&P 500.

Institutional & Insider Ownership

25.3% of Integrated BioPharma shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 67.4% of Integrated BioPharma shares are held by insiders. Comparatively, 55.3% of Dominari shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Integrated BioPharma and Dominari”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integrated BioPharma	$54.35 million	0.10	$810,000.00	($0.07)	-2.58
Dominari	$123.10 million	0.57	-$22.43 million	($4.03)	-0.77

Integrated BioPharma has higher earnings, but lower revenue than Dominari. Integrated BioPharma is trading at a lower price-to-earnings ratio than Dominari, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Integrated BioPharma and Dominari’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Integrated BioPharma	-3.43%	-8.32%	-6.57%
Dominari	-31.37%	-206.20%	-155.26%

About Integrated BioPharma

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

About Dominari

Dominari Holdings Inc., a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as AIkido Pharma Inc. and changed its name to Dominari Holdings Inc. in December 2022. Dominari Holdings Inc. was founded in 1967 and is headquartered in New York, New York.